isis and anp to follow, page-4

One more point to add is my point in earlier posts that Antisense drug development is gaining momentum and pharma are jostling for position.

We are seeing deal being done as soon as after Phase 1 clinical trials, which did not happen before. Big Pharmas are now willing to pay up for a early foothold on any Antisense developments that look promising.

I won't be surprised offers will come in soonest for ANP 's three antisense compounds as the SMA deal was apparently struck over Christmas turkey.

ATL 1102 for MS is at the verge of Phase 3 once the toxicology is fixed.
This would be the big not only in monetary term but for all MS sufferers.